Background. Hepatitis C virus (HCV) is the most common chronic blood-borne infection in the United States and will become an increasing source of morbidity and mortality with aging of the infected population. Our objective was to develop decision analytic models to explore the cost-effectiveness of screening in populations with varying prevalence of HCV and risks for fibrosis progression.
Hepatitis C (HCV) continues to be the most common chronic blood-borne infection in the United States [1] . The most recent National Health and Nutrition Examination Survey (NHANES) analysis estimated that 4.1 million Americans had antibodies to hepatitis C virus (HCV). They further estimated that 3.2 million persons (1.3% of the US population) had chronic infection with HCV [1] .
Chronic infection is associated with significant morbidity and can lead to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) and is the leading cause of liver transplantation in the United States [2, 3] . Not surprisingly, the economic impact of chronic HCV infection is staggering [4] . The estimated lifetime cost of treating currently infected patients is $9 billion in 2012 US dollars, with estimated annual healthcare costs of $360 million [5, 6] .
Previous analyses are almost a decade old or rely on older assumptions and data [7] [8] [9] [10] [11] [12] . The most contemporary models examine a birth cohort born between 1945 and 1970 and make the assumption that fibrosis progresses in a constant fashion through time [12, 13] . Given the significant human and economic burden associated with chronic HCV infection, the age of most prior models, and the variation in approaches and methods used, we developed a decision analytic model to explore the comparative effectiveness and cost-effectiveness of screening in populations with varying prevalence of HCV infection and varying risks for progression of fibrosis. We have focused the model on screening in a community population that consists of both high-risk and lower-risk groups.
METHODS

Review of Data
Population Prevalence
The most recent NHANES analysis estimated an anti-HCV prevalence of 4.1 million Americans (1.6%) [1] . In approximately 22% of HCV antibody-positive patients, viral RNA is absent, representing false-positive enzyme immunoassays (EIAs) and patients who have been infected in the past but no longer harbor virus [14] . Previously infected patients share a number of psychosocial and behavioral risk factors that also afflict patients with chronic HCV infection, including intravenous drug use, alcoholism, and psychiatric disorders. The excess annual mortality associated with these lifestyle risk factors is approximately 0.012 per year (calculated from [15, 16] ; Table 1 ).
Progression of Fibrosis
A number of studies have analyzed the progression of fibrosis in patients with HCV infection. Most have assumed that the rate of progression is constant and thus the cumulative probability of developing cirrhosis increases in a linear fashion over time [17] [18] [19] [20] . More recent studies have suggested that the rate of progression increases from one stage of fibrosis to the next, implying that patients might have minimal fibrosis for many years, followed by a more rapid progression in future years [21, 22] . A series of meta-regressions describing the progression of fibrosis using the Metavir scoring system [23] were developed, based on data from 111 studies of >33 000 individuals with chronic HCV infection [24] . Using data from 4 studies in community settings (n = 279) with a mean patient age of 46.2 at the time of evaluation and a 20.7-year mean duration of HCV infection, stage-specific annual transition probabilities of progression were calculated: 0.124 (F0→F1), 0.086 (F1→F2), 0.124 (F2→F3), and 0.119 (F3→F4).
Fibrosis proceeds until cirrhosis develops (Metavir stage F4). Patients with compensated cirrhosis have a 5-year survival of 84% [25] . As the mean age of patients in this study was 58 years, the relative survival at 5 years, corrected for age (using US Life Tables [26] ) and excess annual mortality risk associated with psychosocial and behavioral factors afflicting patients with HCV, is 93.7%, resulting in an annual excess mortality rate of 1.3% in patients with compensated cirrhosis.
Development of Decompensated Cirrhosis
Once patients have developed compensated cirrhosis, the 5-year cumulative probability of developing a first episode of decompensation (ascites, jaundice, variceal bleed, encephalopathy) is 28%, resulting in a 6.6% annual rate of decompensation [25, 27] . Five-year survival of patients with decompensated cirrhosis is 47%. Relative survival corrected for age and the excess mortality associated with HCV psychosocial behaviors is 52.4%, resulting in an annual excess mortality rate of 12.9% for patients with decompensated cirrhosis.
Development of Hepatocellular Carcinoma
The cumulative 5-year incidence of HCC among HCV-infected patients with cirrhosis is 10%, resulting in an annual rate of 2.1% [25, 28] . Three-year survival without liver transplantation is 6.7% [29] . Correcting for age and excess mortality associated with HCV psychosocial behaviors, the relative survival is 7.3%, resulting in an annual excess mortality rate of 87.2% for patients with HCC.
Liver Transplantation
Patients may receive transplants for either decompensated cirrhosis or HCC [3, [30] [31] [32] . Organs are allocated based upon MELD (Model for End-stage Liver Disease) scores [33, 34] . Patients receive additional priority if they develop HCC. The most recent data from the US Organ Procurement and Transplantation Network (OPTN) list a median wait time of 494 days for patients with MELD scores between 15 and 20, consistent with decompensated cirrhosis [35] . Among patients with MELD scores of 21-30, consistent with HCC, median wait time was 58 days. From these estimates, one can project annual liver transplant rates of 0.51 and 4.36 for patients with decompensated cirrhosis and HCC, respectively. In a study of 4000 consecutive transplant recipients between the years 1981 and 1998, 5-year survival among patients with HCV and decompensated cirrhosis without HCC was 68% [36] . More recent data from the OPTN's Scientific Registry of Transplant Recipients document 5-and 10-year survivals of 72.3% and 56.6%, respectively, among patients receiving liver transplants for noncholestatic cirrhosis [37] . To calculate the 30-day posttransplant mortality, we first determined the annualized mortality rate based on survival at 3 months for all patients undergoing liver transplantation. The 90-day survival of 94.3% resulted in an annualized mortality rate of 23.1%, resulting in a 1-month probability of death of 1.9% (1 -e[−.231/12]) following liver transplant. Backing out 30-day posttransplantation mortality, annualized posttransplantation mortality rates at 3 months, 1 year, 5 years, and 10 years are 11.5%, 9.4%, 4.9%, and 4.9%, respectively.
Among patients receiving liver transplants for HCC, 5-and 10-year survivals are 66.6% and 50.8%, respectively [37] . Using the same methodology as above, we calculated posttransplantation annualized mortality rates at 3 months, 1 year, 5 years, and 10 years to be 9.0%, 10.1%, 6.9%, and 5.4%, respectively.
Treatment of Chronic HCV
Guidelines from the American Association for the Study of Liver Diseases were published in 2009 [62] . More recently, an update for the treatment of genotype 1 infection was published in 2011 [48] . Patients with genotype 1 should be treated with peginterferon, ribavirin, and a protease inhibitor [48] . Patients with other genotypes (2, 3, and 4) are treated with peginterferon and ribavirin [62] . Details of regimens used in our model, including short-course therapy for those with early response in viral loads, can be found in the Supplementary Data. Although liver biopsy is recommended for all patients prior to treatment, we assume that at most 88% undergo biopsy [43] . A significant proportion of patients with chronic HCV infection will not qualify for treatment due to comorbidities, preexisting psychiatric conditions, or alcohol or intravenous drug use [44] [45] [46] . In addition, side effects of interferon-based therapy are significant and many patients choose not to pursue treatment. Ultimately, only 28% of patients identified with chronic HCV infection start treatment [43] .
Description of Simulation Model
We used a commercially available computer program (Decision Maker, Boston, Massachusetts; http://windm.simpal.com/), to develop a Markov state transition model, analyze decision trees, and perform sensitivity analyses, using a lifelong time horizon [63] . Because our analysis focused on the community setting, we used the mean age of 46.2 years and mean duration of HCV infection of 20.7 years, as obtained from the metaregression performed by Thein et al, described earlier [24] , and a gender ratio of 63% males, based on US population data [1] . We considered 2 strategies (Supplementary Figure 1) : no screening vs screening followed by treatment of HCV-infected patients with genotype-appropriate therapy as recommended by current guidelines [48, 62] . We developed a 2-stage simulation model. The first stage is used to model the progression of fibrosis from the time and age of initial infection (Supplementary Figure 2) . The simulation starts with infection at an age of 25.5 years, based on the average for community-dwelling patients in the meta-regression [24] . The simulation stops after 20.7 years and the distribution of fibrosis stages (F0-F4) is then used to seed the starting distribution for the second stage of the model (Supplementary Figure 3) . The second stage involves a more complex Markov model containing 22 states of health (Supplementary Figure 1) . The model considers a population with a distribution of men and women, and races based on US population data, with an average age of 46.2 years. Before entering the Markov node, patients are divided into major clinical subgroups depending on (1) gender, (2) race, (3) presence of antibodies to HCV, (4) test results, (5) chronic HCV infection as documented by viral RNA or (6) resolved HCV infection (antibodies to HCV, but undetectable viral RNA), and (7) HCV and interleukin 28 (IL-28) genotype, if infected. Patients enter the Markov simulation distributed across the 5 fibrosis stages as described above. With each 1-month "tick" of the clock, patients move from one health state to another depending on chance events that may occur. Patients who are uninfected or who have antibodies to HCV but undetectable viral RNA may either die or survive. Patients with fibrosis stages F0-F3 not receiving treatment may either die, remain in their current fibrosis stage, or progress to the next stage of fibrosis. Once cirrhosis develops (fibrosis stage F4), patients may die from nonexplicitly modeled causes (life table based), die from compensated cirrhosis, develop HCC, progress to decompensated cirrhosis, or remain in their current stage. Patients who either develop HCC or progress to decompensated cirrhosis may be considered for liver transplant [64, 65] . Those undergoing transplant may die within the first 30 days. Patients who have developed decompensated cirrhosis or HCC and have not undergone transplant face the same events as those with compensated cirrhosis, although with different probabilities of outcomes. Following liver transplant, we only model death or survival. Details of events modeled among those receiving treatment are presented in the Supplementary Data.
Costs
The analysis was performed from the healthcare system perspective and does not include indirect costs, such as those associated with patients' lost time from work. Costs are expressed in 2011 US dollars. Details of the micro-costing models are described in Table 1 and the Supplementary Data. Future costs and effectiveness were discounted at 3% per year.
Quality of Life
Numerous studies have examined the impact of HCV infection on health-related quality of life [58-60, 66, 67] . We used standard gamble utility assessments calculated by McLernon et al [58] in a meta-regression based on a systematic literature review for HCV with "moderate" disease, compensated cirrhosis, decompensated cirrhosis, and post-liver transplant. Because the meta-regression did not include utilities for patients with HCC, we used standard gamble assessments from a utility study by Chong et al on 193 outpatients with chronic Abbreviations: HCV, hepatitis C virus; QALYs, quality-adjusted life-years. Figure 1 . One-way sensitivity analysis examining the marginal costeffectiveness ratio (mCER) of screening followed by guideline-based treatment as a function of prevalence of chronic hepatitis C virus infection. As prevalence increases, the mCER decreases. Below a prevalence of 0.84%, screening is no longer cost-effective, costing >$50 000 per quality-adjusted life year gained. Abbreviations: HCV, hepatitis C virus; mCER, marginal cost-effectiveness ratio; QALY, quality-adjusted life-year.
HCV for this outcome [59] . Utilities for HCV health states were consistent across the studies by Chong et al, McLernon et al, and Sherman et al [58, 59, 67] .
Calculation of Marginal Cost-Effectiveness Ratios
Strategies are rank ordered by increasing cost, and marginal cost-effectiveness ratios (mCERs) are calculated between each progressively more expensive but effective strategy.
Sensitivity Analyses
We performed both deterministic and probabilistic sensitivity analyses (PSAs) to examine the impact of uncertainty in parameter estimates and population-level variation in parameters.
We conducted PSA using second-order Monte Carlo simulation [68] . Distributions for parameter values were developed (Table 1 ) using β and logit distributions for probabilities and log-normal distributions for relative risks, hazard ratios, and rates. Deterministic sensitivity analyses were performed by systematically varying 1 or more parameter values over clinically relevant ranges.
RESULTS
In the base case (US population, 48.5% male, 77.7% white, 13.3% African American, and 9% Hispanic, with a mean age of 46.2 years; Table 2 ), screening followed by guideline-based treatment (using boceprevir as the direct-acting antiviral [DAA] agent) of those with chronic HCV infection costs $47 276 dollars per additional quality-adjusted life (QALY) year gained. Running the same analysis using telaprevir as the DAA, screening costs roughly the same, $44 074 per additional QALY gained. Figure 1 to show the marginal cost-effectiveness ratio (mCER) of screening as a function of the sum of the risk weights (log odds) for the probability of chronic hepatitis C virus (HCV) infection. A second, lower x-axis shows the prevalence of chronic HCV infection based on the sum of the risk weights at any location on the upper x-axis (note: this results in a logarithmic axis). The table at the bottom of the figure denotes the risk weights for each of the major clinical risk factors. To use the tool, calculate the sum of risk weights for any given patient and then look at the figure to see whether the mCER falls within the region in which screening is cost-effective. If the sum of the risk weights is <2.46, then the mCER of screening is greater than the societal willingness-to-pay threshold of $50 000 per quality-adjusted life-year, and screening is deemed not to be highly cost-effective. Abbreviations: HCV, hepatitis C virus; IDU, injection drug use; mCER, marginal cost-effectiveness ratio; pHCV, probability of chronic hepatitis C infection; QALY, quality-adjusted life-year.
Probabilistic Sensitivity Analysis
Over 10 000 iterations, screening was preferred over no screening 100% of the time, yielding a gain in quality-adjusted life expectancy. As shown in the cost-effectiveness acceptability curve (Supplementary Figure 6) , screening had an mCER <$50 000 per QALY 76% of the time and <$100 000 per QALY 99% of the time. Table 1 shows the confidence intervals and types of distributions used in the PSA.
Deterministic Sensitivity Analyses
HCV prevalence in the United States is between 1.3% and 1.9%. However, prevalence varies markedly among patients with different numbers and types of risk factors. For instance, a white man born between the years 1956 and 1965 with no history of transfusions or intravenous drug use and between 2 and 19 lifetime sexual partners has a predicted HCV prevalence of only 0.6% [1] . The very same patient with a history of intravenous drug use has a predicted HCV prevalence of 46%. As shown in Figure 1 , the mCER of screening decreases as prevalence increases. Below a prevalence of 0.84%, the mCER is greater than the generally accepted societal willingness-to-pay threshold of $50 000 per QALY for highly "costeffective" interventions. Figure 2 shows a screening decision support tool that can be used to quickly calculate the prevalence of HCV based on a small number of demographic and clinical risk factors. The β coefficients from a multivariable logistic regression model were used as risk weights for this tool [1] . If the sum of the risk weights (Supplementary Table 3 and Figure 2 ) is <2.46, then screening for HCV costs >$50 000 per QALY and is not highly cost-effective. Figure 3 summarizes the results of multiple 1-way sensitivity analyses using a tornado plot to examine the cost Figure 3 . Tornado diagram of 1-way sensitivity analyses for the strategy of screening followed by guideline-based treatment. The marginal costeffectiveness ratio in dollars per quality-adjusted life-year (QALY) is shown on the horizontal axis, ranging between zero and $100 000/QALY. For each parameter examined, the upper and lower limits of the sensitivity analysis (labels appear at either end of each band) are based on either the 95% confidence intervals or a clinically reasonable range. £, independent of race; ‡, independent of interleukin 28B genotype and race; †, assuming age of 46 years at time of diagnosis; ¥, low risk = 46-year-old woman with 30-year duration of infection, no history of intravenous drug use (IVDU), alcohol abuse, or transfusions; ¥, high risk = 20-year-old man with 2-year duration of infection, history of IVDU, alcohol abuse, and blood transfusion. Abbreviations: DAA, direct-acting antiviral; EIA, enzyme immunoassay; HCV, hepatitis C virus; IL-28B, interleukin 28B; QALY, quality-adjusted life-year; SVR, sustained virologic response.
effectiveness of screening. Cost-effectiveness is sensitive to a number of parameters, in particular those at the top of the figure. Sensitivity analyses for some parameters capture patient-to-patient variability, such as risk of fibrosis progression, estimated proportion with genotypes 2 and 3, prevalence, quality of life while receiving either pegylated interferon/ribavirin or DAAs, and age at time of infection, whereas other analyses capture uncertainty in parameter values, such as cost of DAA agents, test characteristics, and efficacy of treatment.
DISCUSSION
Older guidelines, such as those of the Centers for Disease Control and Prevention (CDC), supported the screening of high-risk individuals [69] . Health professionals have been urged to routinely ask patients about risk factors for HCV infection. However, current data would suggest that this has not been a successful strategy, with up to three-quarters of HCV infected patients not yet having been identified [41, [70] [71] [72] . Two recent analyses have been published examining the strategy of birth cohort screening of US residents born between 1945 and 1965 [12] or between 1946 and 1970 and have found these to be cost-effective [13] . Just several months ago, the CDC expanded its previous recommendations for the prevention and control of hepatitis C virus infection by promoting birth cohort screening for those born between 1945 and 1965 [73] . However, this approach implicitly assumes that if guidelines supporting birth cohort screening are promulgated, screening will be performed. The failure of current guidelines does not necessarily suggest that guidelines are flawed. More likely, clinicians and the public are not following their recommendations. There are many explanations for this, including lack of clinician and public awareness, limited time for discussion and implementation of the many guidelines primary care physicians are asked to pursue in often chaotic and pressured clinical practice settings, as well as perceptions of limited efficacy and significant side effect profiles of treatment.
We suggest the development of tools to support the implementation of screening guidelines. These may take the form of simple paper and pencil screening decision support tools (see Figure 2) , or, given the proliferation of electronic health records in the United States, electronic alerts to calculate estimated HCV prevalence based on already collected demographic and clinical information. If the estimate exceeds the prevalence threshold of 0.84%, (the $50 000 per QALY willingness-to-pay threshold for cost-effectiveness in this analysis) and the patient has no prior record of being tested, then an order for HCV antibody EIA can be generated. If the estimated prevalence does not exceed the threshold, the system can generate a patient questionnaire that addresses outstanding items, likely questions about prior injection drug use and lifetime sexual partners.
Our analysis addressed a number of modeling issues differently than previous studies. In particular, whereas prior analyses have assumed constant rates of fibrosis progression from one Metavir stage to the next, we used more recent data from a large meta-regression to model variable rates of fibrosis progression for each Metavir stage [24] . Our analysis did not limit the duration of undiagnosed disease prior to screening, as has been done in other analyses [12] . Our analysis explicitly considered the characteristics of screening tests, accounting for the possibility and consequences of false positives and false negatives. We also modeled an increased mortality load among patients who were antibody positive but had undetectable viral RNA loads. Based on data from a large Danish cohort, these patients who have spontaneously cleared HCV are still subject to psychosocial and behavioral factors that put them at increased risk of death from non-HCV-related causes [15, 16] . Given the recent publication of trial results for boceprevir (SPRINT-2) [49] and telaprevir (ILLUMINATE and ADVANCE) [51, 74] and the FDA approval of their use, we have incorporated more recent efficacy and cost data into our analysis. Finally, we also have incorporated IL-28B genotype into our model. This polymorphism has been shown to have a major impact on the likelihood of sustained virologic response among patients with viral genotype 1.
In summary, while our analysis found HCV screening for a mixed gender and racial/ethnic population with a mean age of 46 years in the United States to be cost-effective, more targeted screening for populations with a higher estimated prevalence was found to be even more cost-effective. Ultimately, the impact of any guideline is constrained by its successful implementation. We argue for the development and proliferation of tools to assist in the implementation of guidelines. The increasing use of electronic health records and computerized order entry create new opportunities to marry guidelines to practice. Perhaps in this manner, targeted and cost-effective screening can become a reality for HCV.
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